-
Moderna: Vaccine Efficacy Against COVID-19 Was 94.1%
Moderna: Vaccine Efficacy Against COVID-19 Was 94.1%; Vaccine Efficacy Against Severe COVID-19 Was 100% $MRNA
— *Walter Bloomberg (@DeItaone) November 30, 2020
Added at 7:01am
-
*MODERNA SET TO FILE FOR U.S., EU CLEARANCE FOR COVID-19 VACCINE
— @sellvolbuytesla (@sellvolbuytesla) November 30, 2020
Added at 7:01am
-
*No Serious Safety Concerns Identified With Covid-19 Vaccine, Moderna Says$MRNA
— *Walter Bloomberg (@DeItaone) November 30, 2020
Added at 7:01am
-
MODERNA EXPECTS U.S. FDA ADVISORY COMMITTEE MEETING TO BE SCHEDULED FOR DEC. 17 #News #Forex #US
— Capital Hungry (@Capital_Hungry) November 30, 2020
Added at 7:06am
-
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an ... (full story)
PipsCrapper
OutThere- Story Stats
- Posted: Nov 30, 2020 7:00am
- Submitted by:Category: Low Impact Breaking NewsComments: 2 / Views: 2,621
